Please login to the form below
leukaemia
This page shows the latest leukaemia news and features for those working in and with pharma, biotech and healthcare.
FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies
CAR-T-cell therapy is a type of immunotherapy that involves collecting and using patients’ own immune cells to treat conditions including lymphoma, leukaemia and multiple myeloma.
Latest news
-
Bristol Myers Squibb to acquire Orum’s experimental blood cancer therapy for up to $180m
with acute myeloid leukaemia (AML) or high-risk myelodysplastic syndromes (MDS).
-
Kite and Epic Bio announce cancer cell therapy collaboration agreement
There are three main groups of blood cancer: leukaemia, lymphoma and myeloma. ... recommended for use as an additional treatment for patients aged 26 years and older with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia.
-
FDA approves Servier’s Tibsovo as first targeted therapy for rare blood cancer
The prognosis for these patients has often been associated with worse overall outcomes and an increased risk of transformation to acute myeloid leukaemia (AML).
-
EC approves Otsuka and Astex’s Inaqovi for acute myeloid leukaemia
The European Commission (EC) has approved Otsuka Pharmaceutical and Astex Pharmaceuticals’s Inaqovi (oral decitabine and cedazuridine) as a monotherapy in certain acute myeloid leukaemia (AML) patients. ... AML is a rapidly progressing cancer of the
-
NHS extends eligibility for shingles vaccine to almost one million people
Fiona Hazel, chair of the Blood Cancer Alliance and chief executive officer of Leukaemia UK, said: "If you are living with blood cancer, you are likely to have a weakened immune
More from news
Approximately 95 fully matching, plus 449 partially matching documents found.
Latest Intelligence
-
Parkinson’s disease: past, present and future
Furthermore, inhibitors of the c-ABl pathway, which are currently used to treat leukaemia, have been considered as potentially having neuroprotective effects in Parkinson’s disease.
-
World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
myeloid leukaemia and potential application in other disease states.
-
CAR-T cell therapy in oncology
large B-cell lymphoma, acute lymphoblastic leukaemia and other relapsed/ refractory haematologic cancer. ... tumour antigens, such as CD-19, CD20 and CD22, found predominantly in leukaemia and lymphoma.
-
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
The product underwent its first phase 1 trial test in January 2020 with a patient who was suffering from acute myeloid leukaemia.
-
Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy
symptoms including bladder/ bowel dysfunction, high blood pressure and leukaemia, and can reduce life expectancy by up to 15 years.
More from intelligence
Approximately 1 fully matching, plus 52 partially matching documents found.
Latest appointments
-
Storm Therapeutics bolsters its team
As a clinician-scientist at the University of Melbourne, Professor Dawson has experience in epigenetics having spent several years researching epigenetic regulation of leukaemia stem cells.
-
Helen Parfitt joins Research Partnership
She will also focus on the firm’s recently expanded oncology portfolio, which has added squamous cell carcinoma of the head and neck (SCCHN) and chronic myeloid leukaemia (CML) to its
-
Actinium appoints director of clinical operations
Bergonio moves from Novartis, where he served as an expert clinical manager in the Swiss firm's oncology global development unit, specialising in acute myeloid leukaemia.
-
Astellas bolsters oncology clinical development leadership
breast cancer, leukaemia, lung cancer and prostate cancer.
-
Akinion appoints Dr Richard Jones as CEO
In his new role at Akinion Pharmaceuticals Dr Jones will oversee a company focused on acute myeloid leukaemia and its lead candidate drug AKN-028, a small molecule kinase inhibitor currently
More from appointments
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest from PMHub
-
Article: War in the Blood - The battle takes shape in the burgeoning European oncology CAR-T market access space
The filmmakers followed two leukaemia patients in first-in-human trials in the UK.
-
WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
For instance, CLLSupport (a patient group for those living with chronic lymphocytic leukaemia (CLL)) ran in-person events for those with CLL pre-pandemic, and these events had a huge impact
-
Why you should feel optimistic about the future of healthcare
Precision medicines already exist; imatinib works to treat leukaemia only when the cancer cells have a particular genetic makeup, Sotorasib targets a specific mutation in people with lung cancer to halt
-
Frontera wins at IPA Best of Health 2016
For the Pip award, which aimed to promote the work of the Elimination of Leukaemia Fund (ELF) Mind and Body Service, Frontera was awarded for the ‘White Cell’.
-
Understanding the evolving CAR-T market
The therapy was trialled in paediatric and young adult lymphoblastic leukaemia patients suffering from the most aggressive forms of the disease.
More from PMHub
Approximately 2 fully matching, plus 16 partially matching documents found.
Subscribe to our email news alerts
- World AIDS Day 35: Medscape’s Commitment to the Elimination of HIV through Education and Looking Towards the Future
- No “White Space” Between Live Meetings; the top 10 benefits of virtual advisory boards
- Building trust with HCPs: 6 takeaways from our industry webinar
- Eli Lilly and PRISM BioLab enter drug discovery collaboration worth over $660m
- NHS to offer stem cell transplants to patients living with rare blood disorder
- First WHO Global Clinical Trial Forum develops joint vision to improve clinical research
No results were found
PMHub
AMICULUM
AMICULUM is an independent family of 11 branded agencies that deliver communications and consultancy services to pharmaceutical, biotechnology and health...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
